Enovis (NYSE:ENOV) Azioni

ENOVIS CORP

Enovis

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Enovis Corp

Enova International Inc

Enovix Corp

Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $75 to $70.

News

Price Target

Analyst Ratings

ENOV

Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $70

5 analysts have expressed a variety of opinions on Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Enovis, revealing an average target of $60.8, a high estimate of $64.00, and a low estimate of $55.00. Observing a downward trend, the current average is 4.7% lower than the prior average price target of $63.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1746824443_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Enovis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$64.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Enovis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enovis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enovis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Enovis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENOV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Enovis analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Enovis</h2>
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention &amp; Recovery (P&amp;R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention &amp; Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
<h3>Financial Insights: Enovis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Enovis's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.29% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Enovis's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -125.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Enovis's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -23.87%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Enovis's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.7%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Enovis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Enovis Stands With Analysts

JMP Securities analyst David Turkaly maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Market Outperform and lowers the price target from $62 to $55.

JMP Securities Maintains Market Outperform on Enovis, Lowers Price Target to $55

Needham analyst Mike Matson maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $64 to $57.

Needham Maintains Buy on Enovis, Lowers Price Target to $57

WIIM

Enovis shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 adjusted EPS guidance.

Enovis updated financial expectations for 2025. Revenue is expected to be in the range of $2.22-2.25 billion, versus prior expectations of $2.19-2.22 billion. Adjusted EBITDA is forecasted to be $385-395 million, as compared to the prior outlook of $405-415 million, and now includes $20mm of tariff related impact. Full-year adjusted earnings per share was updated from $3.10-$3.25 to $2.95-$3.10.

Guidance

Enovis Lowers FY2025 Adj EPS Guidance from $3.10-$3.25 to $2.95-$3.10 vs $3.18 Est; Raises FY2025 Sales Guidance from $2.19B-$2.22B to $2.22B-$2.25B vs $2.21B Est

Earnings

Enovis Q1 2025 Adj. EPS $0.81 Beats $0.74 Estimate, Sales $558.83M Miss $558.90M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $64 price target.

Reiteration

Needham Reiterates Buy on Enovis, Maintains $64 Price Target

Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.&nbsp;

Enovis Appoints Damien McDonald as CEO, Effective May 12 2025, Following Matt Trerotola's Retirement

Needham analyst Mike Matson maintains Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and lowers the price target from $65 to $64.

Needham Maintains Buy on Enovis, Lowers Price Target to $64

2025 Financial Outlook
Enovis also announced financial expectations for 2025. Revenue is expected to approximate $2.19-2.22 billion, which incorporates 6-6.5% organic revenue growth. Adjusted EBITDA is forecasted to be $405-415 million, which represents 60-70 basis points expansion year-over-year. Full-year adjusted earnings per share are expected to be in the range of $3.10-$3.25.

Health Care

General

Enovis Expects 2025 Revenue Of Approximately $2.19B-$2.22B, Compared To Consensus Of $2.22B, With Adjusted EPS Of $3.10-$3.25 Vs. $3.16 Est.

Management

Enovis Says Matt Trerotola Will Retire From His Position As CEO, The Board Is Actively Working With An Executive Search Firm To Identify The Company's Next CEO

Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.92 by 6.52 percent. This is a 24.05 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $560.98 million which beat the analyst consensus estimate of $555.15 million by 1.05 percent. This is a 23.29 percent increase over sales of $455.02 million the same period last year.

Enovis Q4 2024 Adj EPS $0.98 Beats $0.92 Estimate, Sales $560.98M Beat $555.15M Estimate

ACAD

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARIS

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), known for its online grocery delivery service Instacart, is trading higher following the announcement that it will join the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42864159/maplebear-set-to-join-s-p-midcap-400-enovis-to-join-s-p-smallcap-600" rel="noreferrer noopener">S&amp;P MidCap 400 index</a>.
This change will see the company replace Enovis Corporation, with Enovis moving to the S&amp;P SmallCap 600. The index changes will take effect prior to the market&#8217;s opening on Tuesday, January 14.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CART stock has gained over 92% in the past year. Investors can gain exposure to the stock via&nbsp;Advisor Managed Portfolios Trenchless Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVER#NYSE">RVER</a>).
In another development, Instacart has formed a nationwide partnership with retailer Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) to offer same-day delivery.
This collaboration introduces same-day delivery options for Ulta Beauty products through Instacart from over 1,400 Ulta locations nationwide.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/01/42878896/dollar-jumps-to-14-month-highs-30-year-yields-near-danger-zone-as-trump-m" rel="noreferrer noopener">Dollar Hits 14-Month High, 30-Year Yields Near Critical Threshold As Trump Reportedly Mulls Economic Emergency Tariffs</a>
The partnership also brings the integration of Ulta Beauty Rewards into the Instacart app, enabling Ulta members to earn rewards points on every Ulta purchase made via Instacart.
Per the press release, new customers can enjoy $10 off orders of $50 or more, valid until January 26.
Blake Wallace, Senior Director of Retail Partnerships at Instacart, expressed excitement about the partnership, noting it would offer customers more convenience and selection, particularly as many are focusing on wellness and self-care in the new year.
Jodi Williams, Vice President of eCommerce at Ulta Beauty, emphasized how the collaboration allows the brand to meet customers in even more places.
This new partnership with Instacart further expands Ulta Beauty&#8217;s reach, joining over 1,500 retailer banners already available on the Instacart platform, which spans categories from grocery to beauty and beyond.
Earlier this week, &nbsp;Ulta announced that&nbsp;Dave Kimbell retired as CEO and stepped down from the <a target="_blank" href="https://www.benzinga.com//node/42832069" rel="noreferrer noopener">company&#8217;s board.</a>
President and COO&nbsp;Kecia Steelman succeeded Kimbell as president and CEO, effective as of Monday. Steelman also joined the company&#8217;s board.
Ulta now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of 11.6% to 12.4% of sales.
Ulta is scheduled to report fourth-quarter financial results on March 13.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ULTA stock has lost over 14% in the past year. Investors can gain exposure to the stock via&nbsp;Neuberger Berman ETF Trust Neuberger Berman Next Generation Connected Consumer ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBCC#NYSE">NBCC</a>).
Price Action: CART shares are trading higher by 5.2% to $45.14 at last check Wednesday, while ULTA shares are trading lower by 3.10% to $415.01.
Read now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42873182/us-private-businesses-add-122000-jobs-in-december-the-labor-market-downshifted-to-a-more-modest-pace-of-growth" target="_blank" rel="noreferrer noopener">US Private Businesses Add 122,000 Jobs In December: &#8216;Slowdown In Both Hiring And Pay Gains&#8217;</a></li>
</ul>
Image via Shutterstock.

Equities

Markets

Movers

ARCH

CART

Neuberger Berman ETF Trust Neuberger Berman Next Generation Connected Consumer ETF

NBCC

RVER

ULTA

Instacart Grows Stronger: S&P MidCap 400 Inclusion, Ulta Partnership Boosts Stock

Enovis To Replace Arch Resources In S&P SmallCap 600 Effective Prior To Opening Of Trading On January 14

Maplebear To Replace Enovis In S&P MidCap 400, Effective Prior To Opening Of Trading On January 14

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $65 price target.

Needham Reiterates Buy on Enovis, Maintains $65 Price Target

Press Releases

Enovis™ Announces Leadership Change to International Surgical Business

Enovis to Host Fourth Quarter and Full Year 2024 Results Conference Call on February 26th

Comments

Enovis

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO